Evidence map›Paper›PMID 40794453›Full record

ArticleThe Journal of clinical investigation2025

Platelet-specific SLFN14 deletion causes macrothrombocytopenia and platelet dysfunction through dysregulated megakaryocyte and platelet gene expression.

Rachel J Stapley, Xenia Sawkulycz, Gabriel H M Araujo, Maximilian Englert, Lourdes Garcia-Quintanilla, Sophie Rm Smith, Amna Ahmed, Elizabeth J Haining, Nayandeep Kaur, Andrea Bacon and 8 more

Abstract read
In one paragraph

Article in The Journal of clinical investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Rachel J StapleyDepartment of Cardiovascular Sciences, School of Medical Sciences, College of Medicine and Health, University of Birmingham, Edgbaston, United Kingdom.
Xenia SawkulyczDepartment of Cardiovascular Sciences, School of Medical Sciences, College of Medicine and Health, University of Birmingham, Edgbaston, United Kingdom.
Gabriel H M AraujoInstitute of Experimental Biomedicine, University Hospital Würzburg, Würzburg, Germany.
Maximilian EnglertInstitute of Experimental Biomedicine, University Hospital Würzburg, Würzburg, Germany.
Lourdes Garcia-QuintanillaDepartment of Cardiovascular Sciences, School of Medical Sciences, College of Medicine and Health, University of Birmingham, Edgbaston, United Kingdom.
Sophie Rm SmithDepartment of Cardiovascular Sciences, School of Medical Sciences, College of Medicine and Health, University of Birmingham, Edgbaston, United Kingdom.
Amna AhmedDepartment of Cardiovascular Sciences, School of Medical Sciences, College of Medicine and Health, University of Birmingham, Edgbaston, United Kingdom.
Elizabeth J HainingDepartment of Cardiovascular Sciences, School of Medical Sciences, College of Medicine and Health, University of Birmingham, Edgbaston, United Kingdom.
Nayandeep KaurDepartment of Cardiovascular Sciences, School of Medical Sciences, College of Medicine and Health, University of Birmingham, Edgbaston, United Kingdom.
Andrea BaconMRC Centre for Immune Regulation, Transgenics Facility, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, United Kingdom.
Andrey V PisarevDepartment of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, New York, USA.
Natalie S PoulterDepartment of Cardiovascular Sciences, School of Medical Sciences, College of Medicine and Health, University of Birmingham, Edgbaston, United Kingdom.
Dean KavanaghDepartment of Cardiovascular Sciences, School of Medical Sciences, College of Medicine and Health, University of Birmingham, Edgbaston, United Kingdom.
Steven G ThomasDepartment of Cardiovascular Sciences, School of Medical Sciences, College of Medicine and Health, University of Birmingham, Edgbaston, United Kingdom.
Samantha J MontagueDepartment of Cardiovascular Sciences, School of Medical Sciences, College of Medicine and Health, University of Birmingham, Edgbaston, United Kingdom.
Julie RayesDepartment of Cardiovascular Sciences, School of Medical Sciences, College of Medicine and Health, University of Birmingham, Edgbaston, United Kingdom.
Zoltan NagyInstitute of Experimental Biomedicine, University Hospital Würzburg, Würzburg, Germany.
Neil V MorganDepartment of Cardiovascular Sciences, School of Medical Sciences, College of Medicine and Health, University of Birmingham, Edgbaston, United Kingdom.

Funding

Alternative mechanisms of different stages in eukaryotic translationR01GM097014 · NIGMS · SUNY DOWNSTATE MEDICAL CENTER · PI HELLEN, CHRISTOPHER ULRICH TRISTRAM · 2012 to 2022
$2.6M
Role of newly discovered SLFN14 in megakaryopoiesis and platelet developmentR01HL146544 · NHLBI · SUNY DOWNSTATE MEDICAL CENTER · PI MORGAN, NEIL, PISAREV, ANDREY · 2020 to 2021
$1.1M
NHLBI NIH HHS R01 HL146544NIGMS NIH HHS R01 GM097014
6 · The paper itself

Abstract

Schlafen 14-related (SLFN14-related) thrombocytopenia is a rare bleeding disorder caused by SLFN14 mutations altering hemostasis in patients with platelet dysfunction. SLFN proteins are highly conserved in mammals where SLFN14 is specifically expressed in megakaryocyte (MK) and erythroblast lineages. The role of SLFN14 in megakaryopoiesis and platelet function has not been elucidated. Therefore, we generated a murine model with a platelet- and MK-specific SLFN14 deletion using platelet factor 4 (PF4) Cre-mediated deletion of exons 2 and 3 in Slfn14 (Slfn14 PF4-Cre) to decipher the molecular mechanisms driving the bleeding phenotype. Slfn14 PF4-Cre+ platelets displayed reduced platelet signaling to thrombin, reduced thrombin formation, increased bleeding tendency, and delayed thrombus formation as assessed by intravital imaging. Moreover, fewer in situ bone marrow MKs were present compared with controls. RNA-Seq and Gene Ontology analysis of MKs and platelets from Slfn14 PF4-Cre homozygous mice revealed altered pathways of ubiquitination, adenosine triphosphate activity, and cytoskeleton and molecular function. In summary, we investigated how SLFN14 deletion in MKs and platelets leads to platelet dysfunction and alters their transcriptome, explaining the platelet dysfunction and bleeding in humans and mice with SLFN14 mutations.

Indexed as

Blood PlateletsGene DeletionGene Expression RegulationMegakaryocytesThrombocytopeniaAnimalsHumansMiceMice, KnockoutGeneticsHematologyMouse modelsPlateletsThrombin

Identifiers

PMID40794453
PMCPMC12520693

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.